尼姆玻利德通过破坏NLRP3炎症酶激活来改善ARDS和性结肠炎
Haowen Xu1, Yao Lin2,3, Weiwei Luo1
1Department of Critical Care Medicine, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Communications biology
|January 10, 2026
概括
尼姆玻化物 (NIM) 是一种天然化合物,有效地抑制NLRP3炎症体,这是炎症性疾病的关键驱动因素. 尼姆显示了双重作用,针对和组装,提供了一个有前途的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- NLRP3炎症酶过活化有助于各种炎症性疾病.
- 开发有效的NLRP3炎症酶抑制剂用于临床使用是具有挑战性的.
研究的目的:
- 为了确定抑制NLRP3炎症酶激活的天然化合物.
- 调查尼姆玻利德 (NIM) 的作用机制和治疗潜力.
主要方法:
- 对天然产品库进行选,以识别NLRP3抑制剂.
- 在体外细胞试验中评估NIM对炎症酶激活,IL-1β分泌和热的作用.
- 在体内研究使用急性呼吸窘迫综合征 (ARDS) 和性结肠炎的小鼠模型.
主要成果:
- 尼姆玻利德 (NIM) 是来自Azadirachta indica的三类化合物,被确定为IL-1β分泌的强有力的抑制剂.
- 剂量依赖的NIM抑制了NLRP3炎症酶激活,Caspase-1裂变,IL-1β释放,以及巨细胞中的热.
- 尼姆对NLRP3具有很高的选择性,通过结合NLRP3 NACHT域中的Lys565来准NF-κB依赖的原始化和炎症酶组合.
- 在ARDS和性结肠炎小鼠模型中,NIM的使用缓解了炎症和病理损伤.
结论:
- 尼姆 (NIM) 是一种天然的抑制剂,具有对NLRP3炎症酶原始化和组装的双重活性.
- 尼姆为治疗NLRP3驱动的炎症性疾病提供了一个有前途的治疗策略.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
448
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
448
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
475
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
475
Drugs for Treatment of Constipation-Predominant IBS
688
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
688
Drugs for Treatment of Diarrhea-Predominant IBS
615
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
615
Inflammatory Bowel Disease IV: Pharmacological Management
463
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
463
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
626
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
626


